Use of ctDNA analysis to complement objective responses detected in patients with advanced HCC treated with GT-EPIC™ based personalized cancer vaccines

Time: 10:00 am
day: Conference Day One


  • Highlighting clinical response data from GNOS-PV02 Phase 1b/2a clinical trial in 2L advanced HCC
  • Use of NeXT Personal® platform (Personalis, Inc.) to longitudinally monitor molecular residual disease (MRD)
  • In a retrospective analysis of patient samples, ultrasensitive tumor informed ctDNA panel identified molecular responses in patients ahead of detection of partial responses (PR) and complete responses (CR) by radiological imaging (RECIST 1.1)